Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Furosemide prices in Germany, the highest-cost reporting region, rose 6.1% in H1 2026, climbing from USD 38.0/KG in Q1 to USD 40.3/KG by Q2 as firmer anthranilic acid synthesis intermediate costs and recovering loop diuretic therapy, heart failure oedema, and hypertensive renal disease formulation procurement reversed the brief Q4 2025 market correction. Globally, the average rose from USD 26.78/KG in Q1 to USD 28.39/KG in Q2, a 6.0% gain. For H2 2026, a global average of USD 28.5-31.9/KG is expected, with continued firming on Middle East supply disruptions and growing loop diuretic, heart failure, and renal disease sector demand globally.
Furosemide is a sulfonamide-derived loop diuretic produced by multi-step synthesis from anthranilic acid through chlorosulfonation, condensation with furfurylamine, and functional group modifications to yield the 4-chloro-2-(furan-2-ylmethylamino)-5-sulphamoylbenzoic acid active molecule. The compound inhibits the sodium-potassium-2-chloride cotransporter NKCC2 in the thick ascending limb of the loop of Henle, blocking tubular reabsorption of sodium, potassium, and chloride ions and generating a powerful, rapid, dose-titratable diuretic response that remains effective across all stages of renal function, including advanced chronic kidney disease where thiazide diuretics lose efficacy. The largest pull comes from chronic heart failure oedema management, where furosemide reduces pulmonary and peripheral fluid overload and improves symptoms across outpatient and hospitalised patient populations. Acute pulmonary oedema intravenous treatment, chronic renal disease oedema, and hypertension in renal impairment add significant demand. Hypercalcaemia management and nephrogenic diabetes insipidus treatment add further niche clinical demand. Anthranilic acid synthesis and chlorosulfonation intermediate costs, heart failure and diuretic prescription volumes, and regional API production capacity all feed into the price.
The balance of supply and demand for Furosemide through H2 2026 leans moderately firm. Anthranilic acid and chlorosulfonation synthesis intermediate costs firmed from Middle East chemical supply disruptions. Heart failure management, renal disease, and diuretic therapy demand are growing with ageing demographics and expanding cardiovascular treatment access.
The main upside risk is synthesis intermediate cost increases alongside accelerating heart failure hospitalisation and diuretic access programme procurement. The main downside risk is Chinese and Indian API surplus and generic competition maintaining price pressure below forecast.
| Region | Price Forecast (USD/KG) | Key Driver |
| Global Average | 28.5 - 31.9 | Synthesis cost firming and heart failure/diuretic demand support |
| United States | 30.0 - 33.4 | Steady heart failure and renal disease demand holds firm |
| China | 21.2 - 24.6 | Large API capacity keeps it the most affordable |
| Germany | 38.6 - 42.0 | High synthesis and energy costs keep it the most expensive |
| India | 29.8 - 33.2 | Growing diuretic and export demand holds a firm middle |
US Furosemide prices averaged USD 32.9/KG in Q2 2026, up 6.1% from USD 31.0/KG in Q1 2026. Firmer synthesis intermediate costs and recovering heart failure oedema and renal disease diuretic procurement drove consistent buying through the quarter.
Why did the price of Furosemide change in Q2 2026 in the United States?
Firmer anthranilic acid synthesis intermediate costs raised the API production floor. Heart failure oedema, acute pulmonary oedema, renal disease, and hypertensive oedema formulation procurement lifted buying. Intravenous loop diuretic demand provided additional support near USD 32.9/KG.
Chinese Furosemide prices averaged USD 22.8/KG in Q2 2026, up 6.0% from USD 21.5/KG in Q1 2026, the lowest among the tracked markets. Spring heart failure and renal disease export and domestic procurement lifted buying. Firmer domestic synthesis costs raised the floor despite large domestic API capacity.
Why did the price of Furosemide change in Q2 2026 in China?
Spring heart failure oedema and renal disease export and domestic procurement lifted buying. Firmer domestic anthranilic acid synthesis costs raised the production floor. Large domestic API capacity kept China the most affordable source.
German Furosemide prices averaged USD 40.3/KG in Q2 2026, up 6.1% from USD 38.0/KG in Q1 2026, the highest among the tracked markets. Higher synthesis intermediate and energy costs elevated European API production economics. Recovering heart failure oedema and renal disease demand maintained buying.
Why did the price of Furosemide change in Q2 2026 in Germany?
Higher anthranilic acid synthesis intermediate and energy costs elevated European API production economics. Middle East supply disruptions added cost premiums to synthesis chains. Recovering heart failure oedema and renal disease diuretic procurement maintained buying near USD 40.3/KG.
Indian Furosemide prices averaged USD 31.2/KG in Q2 2026, up 6.1% from USD 29.4/KG in Q1 2026. Growing heart failure and renal disease export and domestic demand supported buying. Firmer synthesis import costs raised the production floor.
Why did the price of Furosemide change in Q2 2026 in India?
Growing heart failure oedema and renal disease export and domestic procurement lifted buying. Firmer synthesis import costs raised the production floor. Intravenous and oral diuretic export demand provided additional support near USD 31.2/KG.
US Furosemide prices averaged USD 31.0/KG in Q1 2026, recovering about 2.0% from Q4 2025. Recovering heart failure and diuretic demand and firming synthesis costs held the market near USD 31.0/KG.
Why did the price of Furosemide change in Q1 2026 in the United States?
Recovering heart failure oedema and renal disease procurement maintained buying. Firming synthesis intermediate costs raised the production floor. The market recovered to USD 31.0/KG from the Q4 2025 correction.
Chinese prices averaged USD 21.5/KG in Q1 2026, recovering about 1.9% from Q4 2025. Post-Lunar New Year diuretic restocking and firmer synthesis costs held the market near USD 21.5/KG.
Why did the price of Furosemide change in Q1 2026 in China?
Post-Lunar New Year heart failure and diuretic restocking lifted buying. Firming domestic synthesis costs raised the floor. The market recovered to USD 21.5/KG from the Q4 2025 correction.
German prices averaged USD 38.0/KG in Q1 2026, recovering about 1.9% from Q4 2025. Recovering heart failure and diuretic demand and firming synthesis and energy costs held the market near USD 38.0/KG.
Why did the price of Furosemide change in Q1 2026 in Germany?
Recovering heart failure oedema and renal disease procurement maintained buying. Firming synthesis intermediate and energy costs raised the floor. The market recovered to USD 38.0/KG from the Q4 2025 correction.
Indian prices averaged USD 29.4/KG in Q1 2026, recovering about 2.1% from Q4 2025. Growing heart failure and renal disease demand and firmer synthesis import costs held the market near USD 29.4/KG.
Why did the price of Furosemide change in Q1 2026 in India?
Growing heart failure and diuretic procurement maintained buying. Firming synthesis import costs raised the production floor. The market recovered to USD 29.4/KG from the Q4 2025 correction.
Global Furosemide prices rose in Q3 2025 on the diuretic season, dipped in Q4 2025 on synthesis cost moderation, then recovered through Q1 and Q2 2026. The average rose from USD 26.0/KG in Q2 2025 to USD 26.52/KG in Q3, eased to USD 26.25/KG in Q4, then firmed to USD 26.78/KG in Q1 2026 and USD 28.39/KG in Q2 2026, a net gain of about 9.2% over the window. Synthesis intermediate cost cycles and heart failure and diuretic prescription procurement drove the overall pattern.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 28.39 | +6.0% | ↑ Rising |
| Q1 2026 | 26.78 | +2.0% | ↑ Rising |
| Q4 2025 | 26.25 | -1.0% | ↓ Falling |
| Q3 2025 | 26.52 | +2.0% | ↑ Rising |
| Q2 2025 | 26.0 | - | - Stable |
| Q3 2026 | In Progress | - | - In Progress |
Furosemide prices firmed modestly through 2025 on consistent heart failure and diuretic demand. The global average opened near USD 25.8/KG in Q1 2025 and closed at USD 26.25/KG in Q4, a full-year gain of about 1.7%. Synthesis cost dynamics and heart failure and diuretic prescription procurement drove the quarterly pattern throughout the year.
US prices firmed from about USD 30.0/KG in Q1 2025 to USD 30.4/KG by Q4, a gain of 1.3%. Consistent heart failure oedema and renal disease demand maintained the modest upward trend.
Chinese prices firmed from roughly USD 20.8/KG in Q1 2025 to USD 21.1/KG by Q4, a gain of 1.4%. Growing diuretic export and domestic demand drove modest firming.
German prices firmed from about USD 36.9/KG in Q1 2025 to USD 37.3/KG by Q4, a gain of 1.1%. Consistent heart failure and renal disease demand and firm synthesis costs supported the market.
Indian prices firmed from roughly USD 28.5/KG in Q1 2025 to USD 28.8/KG by Q4, a gain of 1.1%. Growing heart failure and diuretic export demand drove modest firming.
Expert Market Research: Your Source for Real-Time Furosemide Price Intelligence
Expert Market Research tracks Furosemide prices continuously across every major producing and consuming region. The team traces causation through anthranilic acid synthesis intermediate economics, heart failure and diuretic prescription cycles, and regional API production capacity. Contact Expert Market Research today for Furosemide pricing data, bespoke market analysis, and strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Chronic heart failure oedema management reducing pulmonary and peripheral fluid overload takes the largest share globally. Acute pulmonary oedema intravenous treatment, chronic renal disease oedema where thiazide diuretics lose efficacy, and hypertension management in patients with renal impairment also consume significant volumes globally.
The Q2 2026 average was USD 32.9/KG in the United States, USD 22.8/KG in China, USD 40.3/KG in Germany, and USD 31.2/KG in India. Germany remains the highest-priced market.
The global average rose from USD 26.78/KG in Q1 to about USD 28.39/KG in Q2, a gain of around 6.0%. Recovering heart failure and renal disease demand and firmer synthesis intermediate costs drove the H1 firming from the Q4 2025 correction.
Anthranilic acid synthesis intermediate cost moderation eased the API production floor. Seasonal heart failure and diuretic procurement moderation reduced buying urgency before the H1 2026 recovery.
The global average is expected in the USD 28.5 to 31.9/KG range for H2 2026, with continued firming as synthesis costs stay elevated and heart failure, renal disease, and loop diuretic demand grows globally.
Germany sits highest on synthesis and energy costs, the United States and India hold a firm middle on heart failure and diuretic demand, and China prices lowest on domestic API production capacity.
This report is updated monthly. For real-time pricing intelligence, contact the Expert Market Research team directly.
Prices respond mainly to anthranilic acid synthesis intermediate costs, heart failure and renal disease prescribing volumes, and cardiovascular treatment access expansion. Synthesis precursor prices and heart failure hospitalisation data are key signals.
China and India hold the largest furosemide API synthesis capacity. Any synthesis intermediate cost shift ripples across markets within one to two quarters.
Buyers can use quarterly trends and forecasts to time heart failure and diuretic formulation contracts around synthesis cost cycles, build cover when intermediate signals tighten, and monitor heart failure prescribing volumes as the primary demand signal.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.